CD Diagnostics is a fully integrated diagnostics company focused on developing immunoassays that improve patient outcomes. The company holds patents on biomarker diagnostics and currently offers seven unique tests. Its first product, Synovasure® PJI, is a joint infection test available as a laboratory developed test in the US, and CE marked in both ELISA plate and lateral flow formats in Europe. CD Diagnostics also provides clinical testing services through its subsidiary CLIA laboratory, Citrano Medical Laboratories. Citrano Medical Laboratories is a key component in the company’s commercialization strategy, as it allows CD Diagnostics to rapidly commercialize products with well-established automated systems for result reporting and billing. Research on the Synovasure infection diagnostic test has led to breakthroughs in the areas of sepsis and bacterial meningitis. These diseases are similar infections, but found in different matrices; synovial fluid, blood, and cerebrospinal fluid respectively. CD Diagnostics’ product developments include direct bacterial antigen detection as well as biomarker detection.
June 15-18, 2015
March 2015CD Diagnostics wins "Best Product Innovation of Zimmer in 2014"
Clin Orthop Relat Res. 2015 Apr 14. [Epub ahead of print]
Clin Orthop Relat Res. 2015 Jan 29. [Epub ahead of print]
Clin Orthop Relat Res. 2014 Oct; 472:3250-3253.